ArticleJCEM case reports2026
A case of thyroid hormone resistance with thyroid regrowth: implications of misdiagnosis on patient care.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a male patient misdiagnosed with resistant hyperthyroidism who erroneously underwent total thyroidectomy complicated by thyroid tissue regrowth. Subsequent iodine-131 (I-131) radiation therapy and medical management further confounded the misdiagnosis. Serological examination in the following years revealed persistently elevated thyroid stimulating hormone (TSH) levels ranging from 45.7 μIU/mL (SI: 45.7 mIU/L) to 134.0 μIU/mL (SI: 134.0 mIU/L) (reference range, 0.550-5.00 μIU/mL [SI: 0.55-5.00 mIU/L]) with variable free thyroxine (FT4) levels ranging from 0.80 ng/dL to 8.1 ng/dL (SI: 10.3 pmol/L to 104.3 pmol/L) (reference range, 0.90-1.70 ng/dL [SI: 11.5-21.8 pmol/L]). Thyroid hormone resistance syndromes (RTH) are characterized by thyroid hormone resistance in organ tissues. Clinical presentation varies based on the severity of thyroid hormone dysregulation and the location of hormone resistance. RTH is often misdiagnosed due to variable phenotypic and biochemical presentations, resulting in erroneous medical and surgical treatments that further complicate patient management. The purpose of this report is to highlight the complex treatment course of this patient and describe challenges faced when diagnosing and managing RTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.